RealFeedApp beta
- TNV313 Phase 1 study doses first subject
Tenvie Therapeutics initiated Phase 1 first-in-human trials for TNV313, a small molecule NLRP3 inhibitor designed to cross the blood-brain barrier. The company plans to publish preliminary safety and pharmacokinetic data in the first half of 2027.
- Field
- drugs and trials
- What they did
- Tenvie Therapeutics started Phase 1 clinical trials for the new drug TNV313, administering the first doses to healthy volunteers.
- Why it matters
- The study aims to evaluate the drug's safety, tolerability, and ability to penetrate the brain while monitoring specific biological markers under different dosing conditions.
#tnv313#nlp3#clinical trial#cns penetration#neurology
